What is AMBOSS?
Headquartered in Berlin, AMBOSS has established itself as a transformative force in the digital health landscape. The company provides a comprehensive knowledge platform that integrates high-yield educational resources for medical students with evidence-based clinical decision support tools for practicing physicians. By bridging the gap between academic learning and point-of-care application, AMBOSS has become an essential utility for the medical community, facilitating improved patient outcomes through streamlined access to verified medical intelligence.
How much funding has AMBOSS raised?
AMBOSS has raised a total of $298.6M across 3 funding rounds:
Series A
$5.6M
Series B
$33M
Other Financing Round
$260M
Series A (2017): $5.6M with participation from Cherry Ventures
Series B (2019): $33M led by Partech, Cherry Ventures, Wellington Partners, Holtzbrinck Digital, and Target Global
Other Financing Round (2025): $260M supported by Kirkbi, Lightrock, and M&G Investments
Key Investors in AMBOSS
Kirkbi
A private holding and investment company that manages long-term assets and maintains majority ownership of the LEGO Group, focusing on sustainable growth and strategic enterprise development.
Lightrock
A global sustainable investment platform managing over $5.5 billion in assets, dedicated to supporting purpose-driven, technology-led companies that address significant global challenges.
M&G Investments
A Switzerland-based firm operating within the venture capital and private equity sector, providing institutional-grade financial support to high-growth enterprises.
What's next for AMBOSS?
With this major enterprise-level funding, AMBOSS is well-positioned to accelerate its international expansion and deepen its technological capabilities. The strategic focus will likely shift toward enhancing its AI-driven clinical insights and scaling its platform to meet the increasing demand for digital health solutions in complex hospital environments. As the company transitions into this next phase of maturity, the focus remains on maintaining its high standards of evidence-based accuracy while expanding its footprint across global healthcare markets.
See full AMBOSS company page
